Dianthus Therapeutics, Inc. Common Stock DNTH

Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.

• GlobeNewswire Inc. 1 oct

  Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  Dianthus Therapeutics granted equity awards to six newly-hired, non-executive employees on October 1, 2026. The inducement grants consist of non-qualified stock options to purchase 106,000 shares of common stock with an exercise price of $88.32 per share and a 10-year term, vesting 25% after one year followed by equal monthly installments over 36 months.

  

• GlobeNewswire Inc. 3 ago

  Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

  Dianthus Therapeutics granted equity awards to six newly-hired non-executive employees on August 3, 2026, consisting of non-qualified stock options to purchase 87,000 shares at an exercise price of $106.02 per share with a 10-year term. The grants were approved by the Compensation Committee as material inducements for employment.

  

• Benzinga 11 jun

  Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position In CIDP, Analyst Says

  Sanofi discontinued its Phase 3 MOBILIZE study of riliprubart for CIDP patients due to failure to meet efficacy objectives. The setback highlights trial design challenges in CIDP studies and may strengthen Argenx's Vyvgart market position, which has demonstrated successful trial execution in the same indication.